SecBot SecBot
SECBOTREPLAY Home › Report › CELC

CELC · Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its…

Celcuity Inc. · 8-K filed Jun 2, 2026 at 08:10 ET

At the news

BULLISHIMPACT 8/10

8-K filed Jun 2, 2026 at 08:10 ET

Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its gedatolisib-triplet (gedatolisib + fulvestrant + palbociclib) doubled median progression-free survival to 11.1 months vs 5.6 months for alpelisib + fulvestrant (HR=0.50, p<0.0001) in PIK3CA-mutant HR+/HER2- advanced breast cancer, with a 48.9% objective response rate and lower discontinuation rates (2.6% vs 7.1%). The company also noted its existing NDA for the wild-type cohort is under Priority Review with a PDUFA date of July 17, 2026, and it plans to submit these data as an sNDA.

  • Gedatolisib-triplet reduced risk of disease progression or death by 50% vs alpelisib + fulvestrant (HR=0.50; 95% CI: 0.37-0.68; p<0.0001)
  • Median PFS: 11.1 months (gedatolisib-triplet) vs 5.6 months (alpelisib + fulvestrant)
  • Objective response rate: 48.9% (gedatolisib-triplet) vs 26.0% (alpelisib + fulvestrant)
  • Treatment discontinuation due to adverse events: 2.6% (gedatolisib-triplet) vs 7.1% (alpelisib + fulvestrant)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access